Summary of adverse events in patients receiving ≥1 onabotulinumtoxinA treatment
| AE, n (%) | Safety population (N=716) |
| Any AE | |
| ≥1 AE | 436 (60.9) |
| Serious AE | 75 (10.5) |
| AE in those who discontinued treatment | 32 (4.5) |
| Treatment-related AE | |
| ≥1 treatment-related AE | 131 (18.3) |
| Serious treatment-related AE | 1 (0.1) |
| Treatment-related AE in those who discontinued treatment | 13 (1.8) |
| Treatment-related AE with incidence ≥1% | |
| Neck pain | 29 (4.1) |
| Eyelid ptosis | 18 (2.5) |
| Musculoskeletal stiffness | 17 (2.4) |
| Injection site pain | 14 (2.0) |
| Headache | 12 (1.7) |
| Muscular weakness | 10 (1.4) |
| Facial paresis | 9 (1.3) |
| Migraine | 7 (1.0) |
| Skin tightness | 7 (1.0) |
Reproduced from Blumenfeld AM, et al,23 available under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).
AE, adverse event.